CytoSorb hemoadsorption of apixaban during cardio-pulmonary bypass for heart transplantation
We observed that CytoSorb could be a potential solution to remove apixaban intraoperatively. If this efficacy is confirmed in larger trials, it would allow transplant candidates to be treated with DOACs without requiring a switch to VKAs.
Authors
- Guillaume Lebreton (ORCID: https://orcid.org/0000-0003-4308-506X)
- Aude Carillion
- Pascal Leprince (ORCID: https://orcid.org/0000-0003-2870-8273)
- Adrien Bouglé (ORCID: https://orcid.org/0000-0002-8990-4705)
- Antoine Abi Lutfallah (ORCID: https://orcid.org/0000-0002-2808-0060)
- Daniel Wendt (ORCID: https://orcid.org/0000-0001-7257-444X)
- Anouk Frering
Institutions
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- CytoSorbents (Germany) (DE)
- Pitié-Salpêtrière Hospital (FR)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- JHLT Open
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1016/j.jhlto.2024.100165
- Citations
- 2
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- CytoSorbents Europe